Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

For Anthony, her plaque psoriasis has remained relatively the same since her diagnosis 10 years ago. "I haven't seen it get worse. I haven't seen it get better.

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

ORLANDO, Fla. — Adults with moderate to severe plaque psoriasis taking the novel oral drug icotrokinra had significant improvement starting at week 16, with increased response rates continuing ...

Opens in a new tab or window ORLANDO -- The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to studies reported here. More than ...

While nearly 8 million Americans live with plaque psoriasis, its impact is often unseen or covered up. 1 Art, whose music has touched millions worldwide, lived silently with his psoriasis—until now.